IR Overview

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). Our lead program, utilizing our NY-ESO TCR therapeutic, has a promising risk/benefit profile to date in Phase I/II trials in solid tumors and in hematologic cancer types. We continue to build a pipeline of TCR therapeutic candidates targeting a number of additional cancer targets, including our MAGE-A10 therapy which has entered initial clinical studies.

$6.990.00 (0.00%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume0
Today's Open$0.00
Previous Close$6.99
Data as of 08/24/16 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
08/08/16Adaptimmune Reports Second Quarter 2016 Financial Results
- Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA and OXFORD, United Kingdom, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2016. Recent Corporate and Clinical Highlights: Received access to Priority Medicines (PRIME) regulatory support from the European Medicines Agency for NY-ESO... 
Printer Friendly Version
08/03/16Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
PHILADELPHIA and OXFORD, United Kingdom, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR® T-cell therapy in myxoid round cell liposarcoma (MRCLS). This trial is not yet active at any investigational sites, and has not recruited any patient... 
Printer Friendly Version
08/02/16Adaptimmune to Report Second Quarter 2016 Financial Results on August 8, 2016
PHILADELPHIA and OXFORD, United Kingdom, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended June 30, 2016 before the open of the U.S. markets on Monday August 8, 2016.  Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. Eastern Time (1:00 p.m. BST) on the same day at which time management will provide a business update and di... 
Printer Friendly Version
07/28/16Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs PHILADELPHIA, Pa. and OXFORD, UK, July 28, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency (EMA) has granted access to its newly-established Priority Medicines (PRIME) regulatory initiative for the company’s SPEAR® T-cell therapy targeting NY-ESO fo... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Notice of Annual General Meeting of Adaptimmune Therapeutics plc
11.00 a.m. London time on Thursday 16 June 2016
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.